Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | MTOR | P42345 | 4/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796521 | 1.00 | RAB9A (0.44) | RAB9ALRRK2HPGDMEN1KMT2A | |
| SCHEMBL17796440 | 0.92 | KMT2A (0.48) | HPGDMEN1KMT2APIK3CAMTOR | |
| SCHEMBL17796675 | 0.92 | KMT2A (0.48) | HPGDMEN1KMT2APIK3CAMTOR | |
| SCHEMBL17804187 | 0.79 | HPGD (0.48) | RAB9AHPGDMEN1KMT2AL3MBTL3 | |
| SCHEMBL17796530 | 0.77 | HPGD (0.56) | LRRK2HPGDLMNA | |
| SCHEMBL17796415 | 0.75 | PIK3CA (0.41) | RAB9AKMT2APIK3CAMTORRORC | |
| SCHEMBL22735368 | 0.72 | CYP46A1 (0.54) | RAB9AHPGDL3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL13618525 | 0.72 | ALDH1A1 (0.62) | HPGDKMT2AALDH1A1 | |
| SCHEMBL16441352 | 0.71 | LRRK2 (0.42) | LRRK2 | |
| SCHEMBL21177577 | 0.70 | RAB9A (0.43) | RAB9AHPGDRORCL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | RAB9A 2304/4885LRRK2 369/4885HPGD 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.